Sinopharm Files for China Approval of COVID-19 Vaccine, Bloomberg Says

Sinopharm has filed for China approval of at least one of its two COVID-19 inactivated vaccines based on initial data from a global Phase III trial, according to a Bloomberg report. However, an unnamed company official disputed that the filing has actually been completed. In any case, it seems that Sinopharm is close to a submission following clinical trials in South America and Middle East countries that enrolled 50,000 volunteers. So far, the company has not released data from the Phase III trials, though it said two weeks ago the vaccine "beat expectations." More details.... Share this with colleagues: // //